Psoriatic Arthritis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

The Psoriatic Arthritis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Sun Pharma, Bristol-Myers Squibb, Affibody/Acelyrin/Inmagene, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Amgen, AbbVie, Abbott, Eli Lilly and Company

[Nevada, United States] - DelveInsight's "Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Psoriatic Arthritis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Psoriatic Arthritis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Psoriatic Arthritis Market Report:
• The Psoriatic Arthritis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
• In October, 2024: Novartis announced that a 28-week, Randomized, Double-blind, Active Controlled, Multicenter Study to Evaluate the Efficacy of Subcutaneously Administered Secukinumab Compared to Ustekinumab in Adult Patients With Psoriatic Arthritis and Failure of TNFα- Inhibitor Treatment (AgAIN)
• In October, 2024: Janssen Research & Development, LLC announced a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis
• In October, 2024: Amgen announced a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD
• In October, 2024: AbbVie announced a Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
• In October, 2024: Eli Lilly and Company announced a study to analyze Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)
• According to the National Psoriatic foundation, about 1 in 3 people or 30% with psoriasis develop psoriatic arthritis (PsA) - as many as 2.4 million Americans - and PsA can develop at any age.
• As per the study by Brent et al. (2024), The prevalence of psoriatic arthritis in patients with psoriasis was 1.7% at 5 years, 3.1% at 10 years, 5.1% at 20 years, and 20.5% at 30 years also The prevalence of psoriatic arthritis in patients with psoriasis is 19.7%, with 21.6% in adults and 3.3% in children.
• As per DelveInsight's assessment, in 2023, most of the PsA cases were of moderate severity, accounting for ~60% cases of pSA, followed by severe and mild types.
• Key Psoriatic Arthritis Companies are as follows: Sun Pharma, Bristol-Myers Squibb, Affibody/Acelyrin/Inmagene, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Amgen, AbbVie, Abbott, Eli Lilly and Company
• Key Psoriatic Arthritis Therapies are as follow: ILUMYA/ILUMETRI (tildrakizumab-asmn), SOTYKTU (deucravacitinib), Izokibep, Secukinumab, Ustekinumab, AIN457, Guselkumab, Apremilast, Adalimumab, Upadacitinib, Ixekizumab, Tirzepatide
• Launching multiple stage Psoriatic Arthritis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Psoriatic Arthritis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Overview:
The current treatment strategy in Psoriatic Arthritis (PsA) emphasizes a target-to-target approach to the prevalent domains. Advances in the knowledge of pathogenesis have led to the development of novel biologics beyond anti-TNFs However, there is still a substantial proportion of patients who may not respond to certain treatment options.

Psoriatic Arthritis Epidemiology Segmentation:
The Psoriatic Arthritis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Psoriatic Arthritis Total Prevalent Cases
• Psoriatic Arthritis Total Diagnosed Cases
• Psoriatic Arthritis Gender-specific Cases
• Psoriatic Arthritis Severity-specific Cases

For more information about Psoriatic Arthritis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Market Insights
Treatment approaches for psoriatic arthritis (PsA) encompass a variety of strategies aimed at managing symptoms, slowing disease progression, and improving overall quality of life. These approaches typically involve a combination of pharmacological therapies, lifestyle modifications, and, in some cases, surgical interventions.

Psoriatic Arthritis Drugs Uptake
• BIMZELX (bimekizumab) by UCB Biopharma is a humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.
• SKYRIZI (risankizumab), developed by AbbVie, is an interleukin-23 (IL-23) antagonist humanized immunoglobulin G1 (IgG1) monoclonal antibody. SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs).
• Developed by Janssen (Johnson & Johnson), TREMFYA (guselkumab) is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor
• ILUMYA/ILUMETRI (tildrakizumab-asmn) by Sun Pharma is an interleukin-23 (IL-23) inhibitor. It is classified as a humanized, anti-IL-23p19 monoclonal antibody and works by blocking inflammatory proteins (cytokines and chemokines) in the body
• SOTYKTU (deucravacitinib) by Bristol-Myers Squibb is the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Therapies and Key Companies:
• ILUMYA/ILUMETRI (tildrakizumab-asmn) : Sun Pharma
• SOTYKTU (deucravacitinib) : Bristol-Myers Squibb
• Izokibep : Affibody/Acelyrin/Inmagene
• Secukinumab, Ustekinumab, AIN457: Novartis Pharmaceuticals
• Guselkumab: Janssen Research & Development, LLC
• Apremilast: Amgen
• Adalimumab, Upadacitinib: AbbVie
• adalimumab: Abbott
• Ixekizumab, Tirzepatide: Eli Lilly and Company

Psoriatic Arthritis Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Psoriatic Arthritis.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Market Drivers:
• Current treatment options for PsA are limited in terms of long term efficacy, tolerability, safety, route of administration, and cost
• The approved therapies have limited adherence among PsA patients and are often associated with treatment gaps
• The development of disease models might help in the understanding of the underlying mechanisms

Psoriatic Arthritis Market Barriers:
• The development of disease models might help in the understanding of the underlying mechanisms that contribute to the development of PsA
• The approval of the multiple drugs has resulted in the entry of the seven different mechanisms of action into the market, which has increased the patient response along with a change in prescription patterns precisely
• PsA is heterogeneous in its clinical presentation and disease course, with substantial morbidity and disability thus, identification of the biomarkers with monitoring of the response is mandated.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Psoriatic Arthritis Market Report:
• Study Period: 2019-2032
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Psoriatic Arthritis Companies: Sun Pharma, Bristol-Myers Squibb, Affibody/Acelyrin/Inmagene, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Amgen, AbbVie, Abbott, Eli Lilly and Company
• Key Psoriatic Arthritis Therapies: ILUMYA/ILUMETRI (tildrakizumab-asmn), SOTYKTU (deucravacitinib), Izokibep, Secukinumab, Ustekinumab, AIN457, Guselkumab, Apremilast, Adalimumab, Upadacitinib, Ixekizumab, Tirzepatide
• Psoriatic Arthritis Therapeutic Assessment: Current marketed and emerging therapies
• Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis Market drivers and Psoriatic Arthritis barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Psoriatic Arthritis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Psoriatic Arthritis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
4. Executive Summary of Psoriatic Arthritis
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey of Psoriatic Arthritis
8. Marketed Products
9. Emerging Therapies
10. Other Assets
11. Psoriatic Arthritis (PsA): Seven Major Market Analysis
12. SWOT Analysis
13. KOL Views
14. Unmet Needs
15. Market Access
16. Acronyms and Abbreviations
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.